Prompted by our recent findings where we established CHEK2 as the first moderate-penetrance testicular germ-cell tumor (TGCT) susceptibility gene and identified the low-penetrance CHEK2 p.Ile157Thr variant as a likely founder missense variant in Croatian men [2], this study aimed to evaluate the PrCa risk conferred by the P/LPs in CHEK2 along with its clinical implications in a Croatian population. This evidence concerns the gene CHEK2 and pure red-cell aplasia.